Almirall and Forest complete Phase III COPD studies
This article was originally published in Scrip
Executive Summary
The Spanish company Almiralland US-based Forest Laboratories have announced the completion of two pivotal Phase III studies designed to assess the efficacy and safety of aclidinium bromide – an anticholinergic bronchodilator – in moderate to severe chronic obstructive pulmonary disease (COPD) patients. Preliminary top-line results are expected later this year. Both trials, one conducted in Europe and the other in North America, were double-blind, multi-centred, parallel-group and placebo-controlled. Patients were aged at least 40, and had a 10 pack year smoking history. The primary end point of both trials is pre-dose forced expiratory volume in one second (a common measure of pulmonary function) versus placebo. Almirall and Forest are co-developing aclidinium bromide; the latter is to market the product in the US while Almirall retains the rights for the rest of the world.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.